Brunner F, Leonhard B, Kukovetz W R, Mayer B
Institut für Pharmakologie und Toxikologie Karl-Franzens-Universität Graz, Austria.
Cardiovasc Res. 1997 Oct;36(1):60-6. doi: 10.1016/s0008-6363(97)00138-7.
We tested the hypothesis that endothelin-1 (ET-1) aggravates ischaemia/reperfusion injury by stimulating cellular L-arginine depletion, which would result in reduced synthesis of nitric oxide (NO) and withdrawal of cardioprotection.
Five groups of rat hearts (n = 5 each) were perfused at 9 ml/min per g for 45 min, subjected to 15 min total global ischaemia and reperfused for 30 min; they received, from 5 min pre-ischaemia to end of reperfusion, either vehicle, L-arginine (1 mmol/l), the NO donor S-nitroso-N-acetyl-DL-penicillamine (SNAP; 200 mumol/l), the inhibitor of NO formation NG-nitro-L-arginine (L-NNA; 200 mumol/l), or the ET receptor antagonist PD 142893 (200 nmol/l). Cardiac function and release of L-arginine, cyclic GMP and lactate dehydrogenase (LDH) into coronary effluent were measured.
Systolic, diastolic, and coronary reperfusion function were consistently improved by L-arginine, SNAP, or PD 142893, but worsened by L-NNA (P < 0.05 in each case). L-arginine release was transiently increased up to 25-fold on reperfusion (vehicle); release was reduced by SNAP (mean: 68%) and entirely prevented by PD 142893. Despite the increased outflow of L-arginine, formation of cyclic GMP was not reduced, but enhanced in reperfusion (11-fold; vehicle), and SNAP further augmented this release, but L-NNA had no significant effect. Release of LDH was decreased by L-arginine, SNAP, and PD 142893 in reperfusion. Finally, release of ET-1 was inhibited by NO in normoxia as well as throughout reperfusion as evident from the stimulatory effect of L-NNA.
In ischaemia, ET-1 cause cell necrosis and L-arginine outflow without compromising NO synthesis in this model.
我们检验了如下假设,即内皮素-1(ET-1)通过刺激细胞内L-精氨酸耗竭加重缺血/再灌注损伤,这将导致一氧化氮(NO)合成减少并失去心脏保护作用。
将五组大鼠心脏(每组n = 5)以每克9毫升/分钟的速度灌注45分钟,进行15分钟全心缺血,然后再灌注30分钟;从缺血前5分钟至再灌注结束,分别给予溶剂、L-精氨酸(1毫摩尔/升)、NO供体S-亚硝基-N-乙酰-DL-青霉胺(SNAP;200微摩尔/升)、NO生成抑制剂NG-硝基-L-精氨酸(L-NNA;200微摩尔/升)或ET受体拮抗剂PD 142893(200纳摩尔/升)。测量心脏功能以及L-精氨酸、环磷酸鸟苷(cGMP)和乳酸脱氢酶(LDH)向冠状动脉流出液中的释放量。
L-精氨酸、SNAP或PD 142893可使收缩功能、舒张功能和冠状动脉再灌注功能持续改善,但L-NNA使其恶化(每种情况P < 0.05)。再灌注时(溶剂组)L-精氨酸释放量短暂增加高达25倍;SNAP使其释放量减少(平均:68%),而PD 142893完全抑制其释放。尽管L-精氨酸流出量增加,但再灌注时cGMP的生成并未减少,反而增加(11倍;溶剂组),SNAP进一步增加其释放量,但L-NNA无显著影响。再灌注时L-精氨酸、SNAP和PD 142893可使LDH释放量减少。最后,从L-NNA的刺激作用可明显看出,在常氧状态下以及整个再灌注过程中,NO均可抑制ET-1的释放。
在该模型中,缺血时ET-1导致细胞坏死和L-精氨酸流出,但不影响NO的合成。